Rehovot, Israel (ots/PRNewswire) - BASED OF THE SATISFACTORY SAFETY DATA OF VIDAC VDA 1102 ON SELECTED PATIENTS VIDAC PHARMA RECEIVED AUTHORIZATION TO WIDEN THE SCOPE OF THE TRIAL TO CTCL WHOLE SPECTRUM OF CONDITIONS. "WE ARE VERY SATISFIED WITH THE RESULTS OF THE FIRST STEP WHICH ON TOP OF THE SAFETY RESULTS GRANTED TO OUR TRIAL A DOSE RANGING PROTOCOL AUTHORIZATION. ...
Rehovot, Israel (ots/PRNewswire) - Vidac Pharma Ltd. announces that it was granted a USA Patent for a new chemical family of compounds targeting the HK2-VDAC system developed by the company. The new compounds are hydrophilic and were developed to fit systemic use such as IV, IM and/or Per-Os use. "This is opening the way to explore possible treatment of solid tumors overexpressing HK2 such as Prostate, Pancreas and other ...
Ness-Ziona, Israel (ots/PRNewswire) - Vidac Pharma LTD (Vidac) a clinical-stage Israel biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS ("GEM") a Luxemburg-based private alternative investment group for a EUR 20 million capital commitment. Under the agreement, GEM commits to provide Vidac with a share subscription facility of up to EUR 20 million for a 36-month term ...